ENVB
Enveric Biosciences Inc
NASDAQ · Pharmaceuticals
$2.37
-0.26 (-9.89%)
Income Statement
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Revenue | 985.8K | 1.01M | 1.10M |
| Net Income | 176.3K | 237.2K | 267.5K |
| EPS | — | — | — |
| Profit Margin | 17.9% | 23.5% | 24.3% |
| Rev Growth | +7.3% | -4.2% | +11.1% |
Balance Sheet
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| Total Debt | 666.0K | 697.3K | 671.8K |
| Total Equity | 1.17M | 1.18M | 1.26M |
| D/E Ratio | 0.57 | 0.59 | 0.53 |
Cash Flow
| FY 2025 | FY 2024 | FY 2023 | |
|---|---|---|---|
| EBITDA | 315.6K | 375.3K | 375.0K |
| Free Cash Flow | 95.4K | 127.9K | 141.2K |